Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Liguria – page 7

810 clinical trials in Liguria, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Liguria at a glance
810
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

810 trials in Liguria

Open in trial search

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Merck Sharp & Dohme LLC

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Delpacibart zotadirsen
  • Sponsor:Avidity Biosciences Inc.

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Tambiciclib Added to Venetoclax and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia in Patients Who Did Not Respond After Two Treatment Cycles

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:IIS La Fe

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:A. Menarini International Licensing S.A.

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Neoplasm

Recruiting

Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

BMN 333 Versus Vosoritide in Children With Achondroplasia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:BMN 333
  • Sponsor:Biomarin Pharmaceutical Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Liguria

What the registry says about research in the country

01 HIV Treatment Research

Clinical research focusing on early treatment switching strategies for HIV-1 infected individuals who have achieved viral suppression. The trials examine the effectiveness of transitioning from three-drug to two-drug antiretroviral therapy.

  • Viral Suppression Maintenance
  • Treatment Simplification
  • Long-term Safety Assessment

The study aims to evaluate a novel approach using dolutegravir/lamivudine combination therapy, potentially offering patients a more streamlined treatment regimen while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.